These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 1056006)

  • 41. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation.
    Janatova J; Lorenz PE; Schechter AN; Prahl JW; Tack BF
    Biochemistry; 1980 Sep; 19(19):4471-8. PubMed ID: 7407085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Localisation of a group of antigenic sites in complement component C3, and identification of a new fragmentation pattern.
    Fontaine M; Sim RB
    Biochim Biophys Acta; 1984 Sep; 789(2):119-27. PubMed ID: 6206896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment, C3d,g.
    Seya T; Nagasawa S
    J Biochem; 1985 Jan; 97(1):373-82. PubMed ID: 3158646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Medof ME; Prince GM; Mold C
    Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H.
    Haque A; Cortes C; Alam MN; Sreedhar M; Ferreira VP; Pangburn MK
    Front Immunol; 2020; 11():1728. PubMed ID: 32849614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation and fragmentation of the third (C3) and the fourth (C4) components of complement: generation and isolation of physiologically relevant fragments C3c and C4c.
    Janatova J; Gobel RJ
    J Immunol Methods; 1985 Dec; 85(1):17-26. PubMed ID: 4078308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of rabbit C3: studies of the generation of cleavage products in vitro and of their metabolism in vivo.
    Peake PW; Charlesworth JA; Pussell BA
    Complement Inflamm; 1991; 8(5-6):261-70. PubMed ID: 1802545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Isolation and characterization of the third complement component of axolotl (Ambystoma mexicanum).
    Avila D; Lambris JD
    Comp Biochem Physiol B; 1990; 95(4):839-45. PubMed ID: 2344737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Purification of the human complement control protein C3b inactivator.
    Crossley LG; Porter RR
    Biochem J; 1980 Oct; 191(1):173-82. PubMed ID: 6451220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
    Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
    J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolation and characterization of the third component of bovine complement.
    Menger M; Aston WP
    Vet Immunol Immunopathol; 1985 Dec; 10(4):317-31. PubMed ID: 3832572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Location of the inter-chain disulfide bonds of the third component of human complement.
    Matsuda T; Seya T; Nagasawa S
    Biochem Biophys Res Commun; 1985 Feb; 127(1):264-9. PubMed ID: 3977921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cleavage of human C5 by trypsin: characterization of the digestion products by gel electrophoresis.
    Minta JO; Man DP
    J Immunol; 1977 Nov; 119(5):1597-1602. PubMed ID: 410877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leishmanial protein kinases phosphorylate components of the complement system.
    Hermoso T; Fishelson Z; Becker SI; Hirschberg K; Jaffe CL
    EMBO J; 1991 Dec; 10(13):4061-7. PubMed ID: 1756717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.